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Quinolones (nalidixic acid - NAL, norfloxacin - NOR, ciprofloxacin - CIP and gatifloxacin - GAT) were tested
against Escherichia coli isolated from urine (385 patient samples) by disk diffusion (DD) and agar dilution (AD)
methods. Fifty-three samples (13.8%) were classified as resistant to at least one of the quinolones tested. CIP and
NOR susceptibilities were the same (91.4%) and they were similar to GAT (92.7%). Susceptibility to NAL, detected
by the disk diffusion method, was used to predict susceptibility to NOR, CIP and GAT by the agar dilution method.
The sensitivity and specificity of NAL were 100% and 95%, respectively. Twelve samples were analyzed for mutations
in the quinolone resistance-determining region (QRDR) of the gyrA and parC genes. Sequencing of these genes
failed to find any mutations in the quinolone-sensitive isolates. However, three mutations were observed in the
isolates resistant to all the quinolones tested - two in gyrA and one in parC. A single mutation in gyrA was found in
the strains that were resistant to nalidixic acid but fluoroquinolone-sensitive. These findings support the suggestion
that NAL could be used as a marker for susceptibility to fluoroquinolones in routine microbiology laboratories. The
overall resistance rate to quinolones in the present study was 13.8%, which is higher than that observed in other
studies carried out in developed countries.  Our findings serve as a warning that resistance to this group of
antimicrobial agents is increasing.
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E. coli is the main etiologic agent of acute urinary tract
infections [3,12], which are usually treated with quinolones
and fluoroquinolones [2,16]. Nalidixic acid was the first
clinically available quinolone. However, because of its
pharmacokinetic properties and the emergence of resistant
isolates, its clinical use has been abandoned [2], although it
continues to be used in some Brazilian medical centers to
treat urinary tract infections in the pediatric population.
The appearance of fluoroquinolone-resistant bacteria was
observed immediately after the introduction of these
antimicrobials into clinical practice to treat infections in
hospitalized patients [16] and community-acquired infections
caused by E. coli [1].
Resistance to fluoroquinolones occurs mainly as a result
of mutations in bacterial gyrA and parC genes that code for
DNA gyrase and topoisomerase IV, respectively [14-16]. Single
mutations in gyrA or parC can cause resistance to the older
quinolones, such as nalidixic acid, as well as a reduction in
the potency of fluoroquinolones, which is reflected in an
increase in the minimal inhibitory concentration (MIC) [6,8,17].
The aim of this study was to evaluate the antimicrobial
activity of quinolones against E. coli isolated from urine as
well as to establish if resistance to nalidixic acid could
constitute a good marker of resistance to the newest
fluoroquinolones. In addition, analyses to detect mutations
in the quinolone resistance-determining region (QRDR) of the
gyrA and parC genes were also carried out in selected isolates.
A total of 385 consecutive Escherichia coli isolates were
obtained from the urine of patients. The patients selected
exhibited urine quantitative counts (≥ 104 CFU/mL) and were
examined by physicians at the Hospital de Clínicas,
Universidade Federal do Paraná (HC-UFPR), between May
and November - 2002. Only one bacterial isolate per patient
was included in the study. These were identified using the
WalkAway® automated system (Dade BehringTM, Sacramento,
USA).
The antibacterial activities of nalidixic acid (NAL),
norfloxacin (NOR), ciprofloxacin (CIP), and gatifloxacin (GAT)
were determined by agar dilution, according to the Clinical
Laboratory Standards Institute (CLSI) guidelines [4]. Nalidixic
acid susceptibility testing was also performed using the disk
diffusion technique as described in the CLSI guidelines [5].
Molecular characterization of quinolone resistance was
carried out by amplification of gyrA and parC genes by PCR
followed by sequencing of the respective amplicons [11,14]
using the Big Dye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems, Foster City, CA) and ABI
BioPrism 3,100 DNA analyzer (Perkin-Elmer Applied
Biosystems, Foster City, CA). Nucleotide sequences and their
deduced protein product alignments were determined using
the Lasergene software package (DNASTAR, Madison, WI).
Most of the E. coli strains (91.2 %) were isolated from
outpatients, and only 8.8% were isolated from hospitalized
patients. The rate of susceptibility to CIP and NOR for the 385
E.coli isolates tested was the same (91.4%) and was slightly
lower than that for gatifloxacin (no longer on the market)
(92.7%) and higher than that for nalidixic acid (86.2%).
Based on the agar dilution MIC results, the 385 E. coli
isolates were divided into three groups: group 1, 332 (86.2%)
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E. coli isolates susceptible to the four quinolones tested;
group 2, 19 (4.9%) E. coli isolates resistant to nalidixic acid
but susceptible to the remaining quinolones; and group 3, 34
(8.8%) E. coli isolates resistant to all four quinolones.
The ciprofloxacin MIC variations were evaluated among
these three groups of strains according to patient gender (Table
I). An interesting finding was that E. coli isolates belonging
to group 3 were more frequently isolated from male than female
patients (p < 0.005). In group 1, CIP MICs varied from ≤ 0.03
μg/mL to 0.12 μg/mL, as shown in Table 2. In this group, 329
E. coli isolates exhibited CIP MICs ≤ 0.03 μg/mL, two strains
exhibited MICs of 0.06 μg/mL, and one strain exhibited a MIC
of 0.012 μg/mL. As expected, the 34 E. coli isolates classified
in group 3 had MICs higher than 2 μg/mL. In group 2, there
was a significant increase in the CIP MICs  (> 0.06 μg/mL)
compared with group 1 (p < 0.005).
Twelve E. coli isolates (two randomly chosen from group
1, five randomly chosen from group 2 and five randomly
chosen from group 3) were submitted to genetic
characterization of the quinolone resistance-determining
region (QRDR) of the gyrA and parC genes. The mutations
found in the QRDR of the gyrA and parC genes are shown in
Table 2. The two E. coli isolates belonging to group 1 did not
show any mutations in the QRDR of the genes studied.
However, the five isolates belonging to group 3 exhibited
double mutations in the gyrA gene (codons 83 and 87) and a
single mutation in the parC gene (codon 80). Of the five E.
coli isolates belonging to group 2, three displayed a single
mutation in the gyrA gene (codon 83). Curiously, one isolate
from group 2 showed no mutation, while the remaining one
showed a single mutation in the QRDR of the gyrA and parC
genes.
A correlation was observed between NAL inhibition zones
and minimal inhibitory concentrations for the fluoroquinolones
(NOR, CIP, GAT), as   illustrated in Figure 1. All the 333 E. coli
isolates exhibiting NAL inhibition zones ≥ 19 mm were also
susceptible to NOR, CIP and GAT. Among the 49 E. coli
isolates resistant to NAL, 32, 33, and 31 isolates were
categorized as resistant to NOR, CIP and GAT, respectively.
The three E. coli isolates that exhibited intermediate resistance
to NAL were susceptible to the fluoroquinolones tested.
For 99% of the E. coli isolates categorized as susceptible
to NAL and CIP, the ciprofloxacin MICs were between 0.015
and 0.03 μg/mL; however, in 13 of 15 E. coli isolates
categorized as resistant to NAL and susceptible to CIP the
corresponding figure was between 0.12 and 0.25 μg/mL. The
same pattern was observed for GAT and NOR. The MICs for
94% of the E. coli isolates susceptible to NAL and GAT were
between 0.03 and 0.06 μg/mL, while the MICs for isolates
resistant to nalidixic acid but susceptible to gatifloxacin were
above 0.25 μg/mL. Thus, the E. coli isolates susceptible to
NOR, CIP and GAT but  with intermediate or full resistance to
nalidixic acid showed an increase in fluoroquinolone MICs of
≥ 2 dilutions compared with fully susceptible E. coli isolates.
When susceptibility to nalidixic acid was assayed by disk
diffusion to predict susceptibility to NOR, CIP and GAT, the
sensitivity and specificity of nalidixic acid were 100% and
95%, respectively. The negative predictive value (NPV) was
100% for the three quinolones studied, while the positive
predictive value (PPV) was 65.4% for NOR and CIP and 63.5%
for GAT.
The present study has shown higher rates of susceptibility
to fluoroquinolones among urinary E. coli isolates collected
from a Brazilian medical center than previously published
studies that investigated Latin American isolates [12,18]. This
difference may be because most of the E. coli in our study
were isolated from outpatients rather than hospitalized patients.
Nalidixic acid inhibition zones correlated with the MICs of
NOR, CIP and GAT. This finding shows that resistance to
NAL can be used as a good indicator of fluoroquinolone
resistance in E. coli. We observed that fluoroquinolone MICs
for isolates that were resistant to NAL but susceptible to
other fluoroquinolones were higher, indicating decreased
susceptibility to these drugs. In addition, the level of
resistance to quinolones depends on the number of
accumulated mutations in the QRDR of the gyrA and parC
genes [20]. Other resistance mechanisms, such as efflux pumps
and alteration in outer membrane permeability, may also be
involved.
A further interesting observation is that the number of
nalidixic acid-resistant strains susceptible to fluoroquinolones
was higher among female patients, while the number of E. coli
isolates that were fully resistant to quinolones was higher in
men, perhaps because of the association between urinary tract
infections and prostatitis, where quinolones are widely used.
Bacteria with reduced susceptibility to quinolones
commonly show mutations in the gyrA gene, which encodes
the subunit gyrA of the DNA gyrase enzyme. These mutations
occur in a region known as the “quinolone resistance-
determining region” (QRDR), which is located between
nucleotides 201 and 320 and encodes amino acid residues 67
to 106 in E. coli gyrA. This is the main mechanism of
quinolone-resistance in Enterobacteriaceae. Mutations in the
gyrB gene have been reported, although they appear to play
a minor role in conferring resistance to quinolones [10,15,16].
Mutations in the genes that encode topoisomerase IV,
particularly the parC gene, correlate with reduced
susceptibility to quinolones. Generally these mutations occur
in amino acid positions 78, 80 and 84, with the substitution of
glycine by aspartate, serine by arginine or isoleucine and
glycine by aspartate, respectively. In the parE gene, mutations
leading to quinolone resistance are not common, although
the substitution of leucine by histidine has been detected at
position 445 [10,17,20].
In order to analyze the correlation between genetic
characterization and resistance phenotype, ten quinolone-
resistant and two quinolone-susceptible E. coli strains were
submitted to amplification and sequencing of the gyrA and
parC QRDR genes (Table 2). The isolates were divided into
groups (1, 2 and 3) according to the quinolone susceptibility
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Table 1. Distribution of ciprofloxacin minimal inhibiting concentrations in 385 E. coli isolates
Quinolone-Resistant Escherichia coli
phenotype; the MICs for ciprofloxacin of the isolates varied.
Of the five strains belonging to Group 2, three E. coli isolates
showed a single mutation in the gyrA gene at position 83
(Ser→Leu) and one E. coli strain showed two mutations, one
in gyrA at position 83 (Ser→Leu) and another  at position 80
of the parC gene (Ser→Arg). E. coli isolates with a single
mutation in gyrA had increased fluoroquinolone MICs, but
these were not high enough to indicate resistance according
to the CLSI breakpoints. However, these isolates were fully
resistant to nalidixic acid. These results are in agreement with
those previously reported [9,11], indicating that nalidixic acid
could be a good marker for single mutations, even when testing
is carried out by the disk diffusion method.
The E. coli strains belonging to group 3 had three mutations:
two in the gyrA gene and one in the parC gene. This confirms
that multiple mutations are necessary to express high levels of
resistance to quinolones. The five strains resistant to CIP encoded
three mutations, two in gyrA at positions 83 (Ser→Leu) and 87
(Asp→Asn) and one in parC at position 80 (Ser→Ile). Only one
E. coli isolate was resistant to nalidixic acid but susceptible to
ciprofloxacin (MIC of 0.25 μg/mL). It displayed two mutations,
one in position 83 (Ser→Leu) of gyrA and the second at position
80 (Ser→Arg) of parC. This result, which was also observed by
other authors, supports the supposition that it is necessary to
accumulate mutations in the primary resistance gene to confer a
high level of resistance to quinolones [7,15,16].
Group 1 - E. coli isolates susceptible to the four quinolones tested; group 2 - isolates resistant to nalidixic acid but susceptible to the
other quinolones; and group 3 - isolates resistant to all four quinolones. N - number of isolates.
Gender Group                                                  Ciprofloxacin (μg/mL) N
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128
1 218 72 290
Female 2 2 3 9 3 17
3 1 3 2 7 3 4 20
327
Male 1 30 9 2 1 42
2 2 2
3 1 4 6 1 2 14
58
Total                385
Table 2. Location and type of mutations in gyrA and parC genes found in selected E. coli isolates
Group 1 - E. coli isolates susceptible to the four quinolones tested; group 2 - isolates resistant to nalidixic acid but susceptible to the other
quinolones; and group 3 - isolates resistant to all four quinolones. NAL - nalidixic acid; CIP - ciprofloxacin.
Strain Group
MIC (μg/mL)                                               Mutation
                gyrA parC
NAL CIP
83                                 87          80
Ser     Ala    Val     Tyr    Asp        Asp   Ser     Ala
5384 1 1 0.03 ..-.........-...........-.........-..........-.. ..-.........-...........-..
9850 1 1 0.015 ..-.........-...........-.........-..........-.. ..-.........-...........-..
837 2 64 0.03 ..-.........-...........-.........-..........-.. ..-.........-...........-..
4633 2 64 0.25 Leu......-...........-.........-..........-.. ..-.........-...........-..
9233 2 64 0.12 Leu......-...........-.........-..........-.. ..-.........-...........-..
4557 2 >512 0.12 Leu......-...........-.........-..........-.. ..-.........-...........-..
8889 2 >512 0.25 Leu......-...........-.........-..........-.. ..-.......Arg........-..
6556 3 >512 8 Leu......-...........-.........-.....Asn ..-........Ile.........-
345 3 >512 64 Leu......-...........-.........-.....Asn ..-.......Ile.........-
6723 3 >512 64 Leu......-...........-.........-.....Asn ..-.......Ile.........-
5850 3 >512 4 Leu......-...........-.........-.....Asn ..-.......Ile.........-
6452 3 >512 32 Leu......-...........-.........-.....Asn ..-.......Ile.........-
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The overall resistance rate to quinolones in the present
study was 13.8%. Although this rate is lower than those
reported by other Latin American studies, it is higher than
those observed in other studies performed in developed
countries [12,19].  Our findings serve as a warning that
resistance to these groups of antimicrobial agents is
increasing.
Testing for susceptibility to nalidixic acid was shown to
be useful as a good predictive marker of susceptibility to
fluoroquinolones in E. coli. The sensitivity of this screening
method was as high as 100% with a specificity of 95%. These
results support the suggestion that nalidixic acid could be
used as a marker for susceptibility to fluoroquinolones in
routine microbiology laboratories.
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